Construction of a pharmaceutical facility of OCTAPHARMA-PHARMIMEX LLC begins in the Ryazan region

OCTAPHARMA-PHARMIMEX LLC begins construction of a facility for the production of medicines based on human blood plasma. The general contractor for the first stage of construction is Metallimpress NPF LLC. The facility, which will have production units including areas for plasma fractionation, cleaning and bottling areas, warehouse for storage of plasma, raw materials and finished products, laboratory complex including analytical laboratory, microbiological laboratory, incoming control laboratory, administrative complex, complex of auxiliary, engineering and technical facilities, is planned to be opened in 2025.

The facility will produce medicines intended for patients in three therapeutic areas: haematology, immunotherapy and critacal care.

Such a large-scale project for the region means not only more than 200 jobs, but also thorough infrastructure development, which includes the construction of roads, a school, a kindergarten and the modernisation of the communal infrastructure in the Skopinsky district.

Andrew Douglas Smith, General Director of OCTAPHARMA-PHARMIMEX LLC, comments: "The start of construction will be a great step for us and for all our partners - the general contractor of the first stage Metallimpress NPF LLC, the company Ceta LLC and, of course, the Administration of Skopinsky District and the Ryazan Oblast government. The implementation of such a unique project is a great responsibility. We are creating the only facility of its kind in Russia, which will definitely become one of the leaders in the pharmaceutical industry".

OCTAPHARMA-PHARMIMEX LLC is a joint venture that includes two legal entities Octapharma AG and JSC “Pharmimex”. The Company was established to construct a plant in the Skopinskiy district of the Ryazan Region and launch full-cycle production of medicines based on human blood plasma in Russia. Octapharma products have been present on the Russian market since 1995.